Fantofarone: Difference between revisions
CSV import |
No edit summary |
||
| Line 23: | Line 23: | ||
{{stub}} | {{stub}} | ||
== Fantofarone gallery == | == Fantofarone gallery == | ||
<gallery> | <gallery> | ||
File:Fantofarone.svg|Fantofarone | File:Fantofarone.svg|Fantofarone | ||
</gallery> | </gallery> | ||
Latest revision as of 21:03, 16 March 2025
Fantofarone is a cardiovascular drug that was developed in the 1990s. It is a 1,4-benzodiazepine derivative that acts as a calcium channel blocker and alpha-1 adrenergic antagonist.
History[edit]
Fantofarone was developed by the pharmaceutical company Sigma-Tau in the 1990s. It was designed to be a cardiovascular drug with a unique mechanism of action, combining the properties of a calcium channel blocker and an alpha-1 adrenergic antagonist.
Pharmacology[edit]
Fantofarone is a 1,4-benzodiazepine derivative. This class of drugs is known for their sedative, anxiolytic, muscle relaxant, and anticonvulsant properties. However, Fantofarone was developed specifically for its cardiovascular effects. It acts as a calcium channel blocker, which means it inhibits the movement of calcium ions into cells. This action can relax and widen blood vessels, reducing blood pressure and improving blood flow.
In addition to its calcium channel blocking activity, Fantofarone also acts as an alpha-1 adrenergic antagonist. This means it blocks the action of adrenaline and noradrenaline on alpha-1 adrenergic receptors. This can further reduce blood pressure and improve blood flow.
Clinical Use[edit]
Despite its promising mechanism of action, Fantofarone has not been widely used in clinical practice. The reasons for this are not entirely clear, but may include a lack of large-scale clinical trials demonstrating its efficacy and safety.
